PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC.
Karlijn HummelinkVincent van den NoortMirte MullerRobert D SchoutenFerry LalezariDennis PetersWillemijn S M E TheelenViktor Hendrik KoelzerKirsten D MertzAlfred ZippeliusMichel van den HeuvelAnnegien BroeksJohn B A G HaanenTon N M SchumacherGerrit A MeijerEgbert F SmitKim MonkhorstDaniela S ThommenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
This study established PD-1T TILs as predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC. Most importantly, the high NPV demonstrates an accurate identification of a patient group without benefit. See related commentary by Anagnostou and Luke, p. 4835.
Keyphrases